MedTrace Logo

Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma

NCT01441661 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2013-03-18

No results posted yet for this study

Summary

This non-interventional study includes patients with advanced renal cell carcinoma who are treated with Sunitinib alone or combined with other systemic therapies. The aim of the trial is to increase knowledge about usage, dosage, efficacy and safety under conditions of routine use of Sunitinib.

Conditions

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Cancer Foundation, China

    lead OTHER

Principal Investigators

  • Zhangqun Ye, MD · Tongji Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01441661 on ClinicalTrials.gov